Skip to Content

Nektar Therapeutics NKTR

Rating as of

Morningstar’s Analysis

There is no Morningtar’s Analysis data available.

Company Profile

Business Description

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Contact
455 Mission Bay Boulevard South
San Francisco, CA, 94158
T +1 415 482-5300
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Slow Growth
Employees 718